Key result
Live-poliovirus vaccines are undergoing rapid development for protection against paralytic poliomyelitis despite the availability of the inactivated Salk-type vaccine.
Answers are grounded in this paper and cite their sources.
Discusses the development and potential advantages of live-virus polio vaccines over the inactivated Salk-type vaccine.
There has recently been a rapid acceleration of activity and a marked increase in interest in the development of live-virus vaccines for protection against paralytic poliomyelitis that may be expected to be climaxed soon by their introduction into general use. Interestingly enough, this activity has proceeded in spite of the availability of large amounts of the inactivated, Salk-type vaccine, which is still the only officially approved and recommended form. However, the need for repeated injections, its failure to provide rapid protection in the face of an epidemic, the not insignificant cost, reasonable though it may be, and particularly the recent . . .
No takes yet. Share an insight, caveat, or question.
A 1959 study conducted an editorial in paralytic poliomyelitis. Live-Poliovirus Vaccine vs. inactivated, Salk-type vaccine was evaluated. Live-poliovirus vaccines are undergoing rapid development for protection against paralytic poliomyelitis despite the availability of the inactivated Salk-type vaccine.
Synapse has enriched 10 related papers. Consider them for comparative context: